Participants with histologically confirmed persistent, recurrent or metastatic cervical cancer (SCC, adenocarcinoma, and adenosquamous carcinoma) who are not amenable to curative therapy
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 2 Drug TrialEarly stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
-
ERM Project ID
114041
Trial contact details
-
Contact person
RIO Clinical Trials
-
Phone
07 3163 1369
What you need to know
Who can take part?
Participants with histologically confirmed persistent, recurrent or metastatic cervical cancer (SCC, adenocarcinoma, and adenosquamous carcinoma) who are not amenable to curative therapy
Participants with histologically confirmed hepatocellular carcinoma who are not amenable to curative therapy and ineligible for loco-regional therapy
Participants with cytologically or histologically confirmed advanced, recurrent or metastatic disease, which is not amenable to curative therapy, in up to 5 types of solid tumour with moderate to high median TMB (NSCLC, urothelial, SCCHN, gastric/gastro-oesophageal adenocarcinoma, oesophageal SCC).
What i involved for me?
The study drug is provided as capsules that are swallowed with water.
You will take the capsules twice a day, once in the morning and once in the evening for 3 weeks at a time.
Cemiplimab will be administered as an intravenous infusion over 30 minutes. The infusion is given every 3 weeks. Each infusion of cemiplimab will be administered in the clinic, under the supervision of site staff.
